Phio Pharmaceuticals (PHIO)

NASDAQ:PHIO

PHIO

Phio Pharmaceuticals

RESEARCH TOOLSreports

Phio Pharmaceuticals (PHIO) Price & Analysis

648 Followers

PHIO Stock Chart & Stats

$1.19

-$0.09(-4.97%)

At close: Jan 08 4:00 PM EST

$1.19

-$0.09(-4.97%)

Day’s Range― - ―

52-Week Range$0.81 - $4.19

Previous CloseN/A

Volume62.29K

Average Volume (3M)137.46K

Market Cap

$14.06M

Enterprise Value-$6.97M

Total Cash (Recent Filing)$21.03M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.41

Next Earnings

May 07, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding11,617,250

10 Day Avg. Volume82,534

30 Day Avg. Volume137,459

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.31

Price to Sales (P/S)0.00

P/FCF Ratio-0.79

Enterprise Value/Market Cap-0.50

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit6.48

Enterprise Value/Ebitda0.77

Forecast

1Y Price Target

$14.00

Price Target Upside1076.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 1b data showed a high rate of pathologic responses in treated cutaneous skin cancer patients, including multiple complete clearances, indicating meaningful anti-tumor activity for PH-762.

Regulatory PathwayPlanned engagement with the FDA to define next clinical steps could clarify the development pathway and improve commercial visibility for the INTASYL delivery platform.

Safety ProfilePH-762 exhibited a consistent safety profile with no dose-limiting toxicities or serious treatment-related adverse events reported, supporting continued clinical evaluation.

Bears Say

Data MaturityCurrent findings are preliminary and require additional data to confirm durability of responses and applicability across broader patient populations.

Development RiskPH-762 remains in early clinical development, which creates substantial uncertainty around long-term outcomes and the likelihood of regulatory approval.

Phio Pharmaceuticals News

Phio Pharmaceuticals Establishes New At-the-Market Equity Program

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On April 8, 2026, Phio Pharmaceuticals entered into an...

5d ago

PHIO

Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On March 30, 2026, Phio Pharmaceuticals announced it had...

15d ago

PHIO

Buy Rating on PHIO: Strong Early PH-762 Clinical Data and Solid Cash Runway Support Upside Potential

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of...

1M ago

PHIO

Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation

The latest update is out from Phio Pharmaceuticals ( ($PHIO) ). On February 17, 2026, Phio Pharmaceuticals Corp....

2M ago

PHIO

Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results

Phio Pharmaceuticals ( ($PHIO) ) has shared an announcement. On February 10, 2026, Phio Pharmaceuticals reported that an...

2M ago

PHIO

Buy Rating on Phio Pharmaceuticals: Early PH-762 Efficacy, Clean Safety Profile, and Solid Cash Runway Support Favorable Risk–Reward

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of...

3M ago

PHIO

Phio Reports Positive Phase 1b PH-762 Skin Cancer Data

The latest announcement is out from Phio Pharmaceuticals ( ($PHIO) ). On January 20, 2026, Phio Pharmaceuticals reported...

3M ago

PHIO

Phio Advances PH-762 With FDA-Backed Toxicology Study

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the...

4M ago

PHIO

Phio Pharmaceuticals Completes Enrollment for PH-762 Trial

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On November 25, 2025, Phio Pharmaceuticals announced the completion...

5M ago

PHIO

Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders

The company will not receive any of the proceeds from the sale by the selling stockholders of the...

5M ago

PHIO

Phio Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating

H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Phio Pharmaceuticals today and set a price target...

5M ago

PHIO

Phio Pharmaceuticals files to sell 1.93M shares of common stock for holders

06:08 EDT Phio Pharmaceuticals (PHIO) files to sell 1.93M shares of common stock for holders Published first on...

8M ago

PHIO

Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Phio Pharmaceuticals (PHIO) with a Buy rating and $14 price target Phio’s lead...

10M ago

PHIO

Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders

16:41 EST Phio Pharmaceuticals (PHIO) files to sell 5.93M shares of common stock for holders Published first on...

1y ago

PHIO

PHIO FAQ

What was Phio Pharmaceuticals’s price range in the past 12 months?

Phio Pharmaceuticals lowest stock price was $0.81 and its highest was $4.19 in the past 12 months.

What is Phio Pharmaceuticals’s market cap?

Phio Pharmaceuticals’s market cap is $14.06M.

When is Phio Pharmaceuticals’s upcoming earnings report date?

Phio Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 23 days.

How were Phio Pharmaceuticals’s earnings last quarter?

Phio Pharmaceuticals released its earnings results on Mar 05, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.19.

Is Phio Pharmaceuticals overvalued?

According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Phio Pharmaceuticals pay dividends?

Phio Pharmaceuticals does not currently pay dividends.

What is Phio Pharmaceuticals’s EPS estimate?

Phio Pharmaceuticals’s EPS estimate is -0.24.

How many shares outstanding does Phio Pharmaceuticals have?

Phio Pharmaceuticals has 11,617,250 shares outstanding.

What happened to Phio Pharmaceuticals’s price movement after its last earnings report?

Phio Pharmaceuticals reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went down -0.855%.

Which hedge fund is a major shareholder of Phio Pharmaceuticals?

Currently, no hedge funds are holding shares in PHIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Phio Pharmaceuticals (PHIO) Earnings & Revenues

Historic Earnings Reports

PHIO Stock 12 Month Forecast

Average Price Target

$14.00

▲(1076.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.02,2.0184615384615388,3.016923076923077,4.015384615384615,5.0138461538461545,6.012307692307692,7.010769230769231,8.00923076923077,9.007692307692308,10.006153846153847,11.004615384615384,12.003076923076923,13.001538461538463,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.02,2.0184615384615388,3.016923076923077,4.015384615384615,5.0138461538461545,6.012307692307692,7.010769230769231,8.00923076923077,9.007692307692308,10.006153846153847,11.004615384615384,12.003076923076923,13.001538461538463,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.02,2.0184615384615388,3.016923076923077,4.015384615384615,5.0138461538461545,6.012307692307692,7.010769230769231,8.00923076923077,9.007692307692308,10.006153846153847,11.004615384615384,12.003076923076923,13.001538461538463,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.92,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.987,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >